Voyager Therapeutics Культура компании

Dr. Guangping Gao, Ph.D is the Founder Voyager Therapeutics, Inc. Dr. Gao is the Founding Director of the Gene Therapy Center and Vector Core, the Scientific Director of the UMMS-China Translational Research Initiative and Professor of Microbiology and Physiology Systems at UMMS since 2008. Dr. Gao is an internationally recognized AAV and gene therapy researcher who has played a key role in the discovery and characterization of new AAV serotypes. Dr. Gao made major contributions to the development of the 3rd generation adenovirus vectors and since 1996, he served as Assistant Director of the Institute for Human Gene Therapy (IHGT) at the University of Pennsylvania with primary responsibility for clinical adenovirus vector production. He served as Associate Director and Director of the vector program of IHGT to oversee the vector discovery and development, process development, and vector core and quality control testing. He was the driving force behind the discovery and vectorology of a novel primate AAV family for gene therapy and the development of simian adenovirus vector-based vaccine programs. He serves on the advisory board of Advances in Experimental Medicine and Biology and the editorial boards of Human Gene Therapy and Gene Therapy, Molecular and Cellular Therapy and Journal of Neurological Disorders. In 2010, he was officially named the Penelope Booth Rockwell Professor in Biomedical Research. Dr. Gao has published more than 150 papers in peer-reviewed journals and has 26 patented inventions. Dr. Gao is the senior editor of the book series on Gene and Cell Therapy published by ASGCT and Springer Publisher. Dr. Gao holds a Bachelor's degree in medicine from the West China Medical School of Sichuan University and a Ph.D. in molecular genetics from Florida International University.

Dr. Robert G. Pietrusko, also known as Bob, Pharm. D., has been Senior Vice President of Regulatory Affairs and Quality Assurance at Voyager Therapeutics, Inc. since June 2014. Dr. Pietrusko oversee all strategy and interactions with the U.S. Food and Drug Administration (FDA) and other agencies. He served as Vice President of Global Regulatory Affairs and Quality at ViroPharma Inc., since May 1, 2007 and serves as its Executive Officer. He oversaw the planning, implementation and optimization of ViroPharma's worldwide quality and regulatory strategies. His focus helped to guide the development of ViroPharma's key pipeline opportunities, including maribavir, HCV-796 and NTCD; providing regulatory support for ViroPharma's physician education efforts in C. difficile-associated disease and assuring patient safety; providing additional leadership in quality assurance and compliance; and providing regulatory strategy and support for any additional compounds acquired by ViroPharma. He served as Senior Vice President of worldwide regulatory affairs for Millennium Pharmaceuticals Inc., from 2001 through May 2007. At Millennium Pharmaceuticals, Dr. Pietrusko was responsible for the global regulatory affairs function and strategy, where he was instrumental in the approval of Millennium's products, including the accelerated approval and worldwide regulatory strategy for Velcade, a product approved in over 75 countries worldwide. Prior to Millennium, he spent 19 years at GlaxoSmithKline (SmithKline Beecham), culminating in his tenure as Vice President and Director of anti-infective and antiviral therapeutic areas, U.S. regulatory affairs, where he led the anti-infective and antiviral regulatory groups. During his tenure at GlaxoSmithKline, Dr. Pietrusko was instrumental in approvals for products including Havrix, Augmentin(R) XR and ES (amoxicillin/clavulanate potassium) for bacterial sinusitis and community-acquired pneumonia and Infanrix(R) (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed). Dr. Pietrusko directed the submission of more than 20 NDAs, sNDAs and BLAs to the U.S. Food and Drug Administration (FDA) including antibiotics, anti-virals, vaccines, oncologics, cardiovascular products, pulmonary products and anti inflammatory compounds. He serves as a Member of Advisory Board at Kinderpharm LLC. He is directly responsible for organizing and leading eight FDA Advisory Committee presentations. He completed his residency training at Thomas Jefferson University Hospital. He is the author or co-author of 52 scientific publications. Dr. Pietrusko holds a Bachelor of Science degree in biology and a Bachelors of Pharmacy degree from Rutgers University and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science.

Dr. Dinah Sah, Ph.D., has been a Chief Scientific Officer at Voyager Therapeutics, Inc. since January 2017. Dr. Sah served as Senior Vice President of Neuroscience at Voyager Therapeutics, Inc. since March 2014. Dr. Sah served as a Vice President of Research for CNS and Oncology at Alnylam Pharmaceuticals, Inc., since October 2008. She has more than 20 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Sah has led multiple programs from early research through Phase 1 clinical trials, as well as discovering novel therapeutic targets and drug candidates that have advanced into clinical development. Her leadership of several RNAi therapeutics R&D programs resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs. Before joining Voyager, Dr. Sah spent seven years at Alnylam Pharmaceuticals, where she was most recently Vice President of Research, providing scientific leadership and administrative oversight of discovery research and multiple research and development programs. Dr. Sah led the Huntington's program in collaboration with Medtronic, as well as the JCV program in collaboration with Biogen Idec at Alnylam. Dr. Sah joined Alnylam in April 2005 as Senior Director, Research, after having served as Associate Director, Research, at Biogen Idec, where she led neurobiology research since 1999. At Alnylam, she established and helped build the CNS and Oncology efforts, including ALN-VSP. While at Biogen, Dr. Sah led research efforts in neuroscience and strategic planning for the neurobiology focus area and was project leader of several research programs, including pain and spinal cord injury. From 1993 to 1999, Dr. Sah served as a Scientist and then Associate Director of Neurobiology at Signal Pharmaceuticals in San Diego where she was project leader for neuroscience collaborations with Roche and Nippon Kayaku. She is an inventor on more than 25 patents and her publications across diverse research areas include 18 articles in the New England Journal of Medicine, Nature Medicine, Nature Biotechnology, Nature Neuroscience, Nature Chemical Biology, Nature Reviews Drug Discovery, Molecular Therapeutics, Neuron, PNAS and EMBO Journal. She completed her post-doctoral training at Harvard Medical School and received her Ph.D. in Neurobiology from Harvard University.

Dr. Krystof Bankiewicz M.D., Ph.D. is an Advisor of MRI Interventions, Inc. Dr. Bankiewicz is Founder of Voyager Therapeutics, Inc. He is a leader in AAV gene therapy and has brought multiple AAV therapies to the clinic. He has both industry and academic experience. He has considerable experience in supervising multi-investigator translational programs and is a principal investigator on several multi-center, multi-investigator grants and clinical trials. His main area of expertise focuses on in vivo models of Parkinson's disease, neuroimaging, the dopaminergic system and convection-enhanced delivery of viral vectors in the brain. Dr. Bankiewicz serves as a Member of Ced Advisory Committee MedGenesis Therapeutix Inc., and served as its Member of the Scientific Advisory Board. He also serves as a Member of Advisory Board of Oxford Biomedica Plc and SanBio Inc. He served as a Member of CNS Scientific Advisory Board at uniQure N.V. (formerly, uniQure BV). He is the Kinetics Foundation Chair in Translational Research and Professor in Residence of Neurological Surgery and Neurology at the University of California at San Francisco (UCSF). Dr. Bankiewicz is also Vice Chair for Research in the Department of Neurosurgery and Director of Interventional Neurology Center at UCSF. He has created a world class laboratory at the University of California, San Francisco, focusing on the delivery of therapeutic agents into the central nervous system through automated cell-implantation, convection-enhanced and gene transfer-based delivery methods, as well as in vivo applications of MRI and PET to detect in-vivo changes in brain and their correlation with functional outcome. He is an inventor on numerous patents and has published more than 180 peer-reviewed research articles. He has supervised a total of 35 postdoctoral fellows and manages a core research group of 20 people, including technicians, postdoctoral fellows and senior scientists. Throughout his career, Dr. Bankiewicz has maintained a strong focus on the development of translational approaches to gene and cell replacement therapies and he has displayed the ability to synthesize distinct technologies into powerful new approaches to the treatment of serious diseases, including brain cancer, Parkinson's disease, Huntington's disease, Alzheimer's disease, pediatric neurotransmitter deficiency and lysosomal storage disorders. Dr. Bankiewicz holds several patents, including those for use of neuro-derived fetal cell lines for transplantation therapy, convection-enhanced delivery of adeno-associated virus (AAV) vectors and CED of AAV viral vector with AADC for the treatment of Parkinson's disease. He is internationally recognized for his work on gene and cell delivery into the central nervous system. Dr. Bankiewicz was a recipient of Fogarty Fellowship and trained at the National Institutes of Neurological Disorders and Stroke at NIH, Bethesda, Md. Dr. Bankiewicz holds an M.D. from Jagiellonian University in Crakow and a Ph.D., D.Sc., from the Institute of Neurology and Psychiatry in Warsaw, Poland and Professor title by the President of Republic of Poland.

Allison Dorval serves as the CFO of Voyager Therapeutics, Inc.. Allison started at Voyager Therapeutics, Inc. in Nov of 2018. Allison currently resides in the Greater Boston Area.